BlackRock Health Sciences Term Trust (NYSE:BMEZ) Announces $0.18 Monthly Dividend

BlackRock Health Sciences Term Trust (NYSE:BMEZ) announced a monthly dividend on Friday, December 6th,NASDAQ Dividends reports. Shareholders of record on Monday, December 16th will be paid a dividend of 0.1781 per share on Monday, December 23rd. This represents a $2.14 annualized dividend and a dividend yield of 13.81%. The ex-dividend date of this dividend is Monday, December 16th.

BlackRock Health Sciences Term Trust has increased its dividend payment by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Stock Down 0.1 %

Shares of NYSE:BMEZ traded down 0.02 during midday trading on Friday, hitting 15.48. The company had a trading volume of 360,200 shares, compared to its average volume of 277,112. BlackRock Health Sciences Term Trust has a 12 month low of 14.38 and a 12 month high of 16.59. The firm has a fifty day simple moving average of 15.61 and a 200 day simple moving average of 15.62.

Insiders Place Their Bets

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. bought 29,795 shares of BlackRock Health Sciences Term Trust stock in a transaction on Wednesday, October 16th. The shares were purchased at an average cost of 15.81 per share, for a total transaction of 471,058.95. Following the completion of the acquisition, the insider now owns 20,750,913 shares in the company, valued at approximately 328,071,934.53. The trade was a 0.14 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have purchased 99,630 shares of company stock worth $1,585,113.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.